← Eichor
Condition: Neuroendocrine Tumor Grade 1 Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neuroendocrine Tumor Grade 1

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
Phase 2 · 4 location(s) · Shanghai Chest Hospital · NCT07357623Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Phase 3 · 65 location(s) · Novartis Pharmaceuticals · NCT06784752Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for
Phase 1 · 1 location(s) · Stanford University · NCT04609592Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Phase N/A · 1 location(s) · University of Roma La Sapienza · NCT04464122Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06228066Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors
NA · 1 location(s) · Institut Paoli-Calmettes · NCT04520932Life Following Excision of Neuroendocrine Tumors
Phase N/A · 1 location(s) · Sunnybrook Health Sciences Centre · NCT06981455Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
Phase 2/Phase 3 · 1 location(s) · The Netherlands Cancer Institute · NCT06855095IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif
Phase 1 · 1 location(s) · Peter Hosein, MD · NCT06889493Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
NA · 1 location(s) · Emory University · NCT04278118Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
Phase 2 · 1 location(s) · University of Iowa · NCT06395402Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms
NA · 1 location(s) · Oslo University Hospital · NCT05243082Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 · 3 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT07517198FTT PET/CT in Pancreatic Neuroendocrine Tumors
Phase 1 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT07114939Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Phase 2 · 2 location(s) · AC Camargo Cancer Center · NCT06472388PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
Phase 3 · 2 location(s) · Tata Memorial Hospital · NCT07185672Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06161532Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Phase 2 · 1 location(s) · University of California, San Francisco · NCT05746208Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not
NA · 4 location(s) · Uppsala University · NCT07273409Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
Phase 2 · 12 location(s) · Australasian Gastro-Intestinal Trials Group · NCT06345079
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.